Previous 10 | Next 10 |
FDA has signed-off investigational new drug application ((IND)) filed by Eli Lilly ([[LLY]] +0.3%) for LY3561774, the first candidate to emerge from licensing collaboration between Dicerna ([[DRNA]] -3.8%), and Eli Lilly.The event has triggered a milestone payment of $10M from Eli Lilly,...
– Data Presentations Show Treatment With Up to Four Monthly Doses of RG6346 Resulted in Substantial and Durable Reductions in HBsAg Levels Lasting Up to One Year After Last Dose – – RG6346 Was Shown to be Safe and Well Tolerated in This Trial – ...
— Milestone Achievement Reflects First Investigational Candidate to Emerge Under Multi-Target Collaboration and Triggers $10 Million Payment to Dicerna — – Lilly Targeting Initiation of Phase 1 Clinical Trial of LY3561774 by Year-End 2020 – ...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Marc Abrams, Ph.D., vice president of discovery research, will presen...
Image source: The Motley Fool. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) Q3 2020 Earnings Call Nov 5, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Dicerna Pharmaceuticals Inc (DRNA) Q3 2020 Earnings Call Transcr...
Dicerna Pharmaceuticals (DRNA): Q3 GAAP EPS of -$0.29 misses by $0.05.Revenue of $48.9M (+508.2% Y/Y) misses by $2.81M.Press Release For further details see: Dicerna Pharmaceuticals EPS misses by $0.05, misses on revenue
– Company Targeting Enrollment Completion for Pivotal PHYOX™2 Trial of Nedosiran in Fourth Quarter 2020 – – Company Reported $609.9 Million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2020 – – Manage...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that updated data related to RG6346, an investigational GalXC™ RNAi...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that the Company will release its third quarter 2020 financial results aft...
Dicerna Pharmaceuticals ([[DRNA]] +3.3%) announces positive preliminary data from a Phase 3 clinical trial, PHYOX3, evaluating once-monthly RNAi therapeutic nedosiran in patients with the three known types of primary hyperoxaluria (PH1, PH2 and PH3), a rare inherited disorder caused by excess...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...